H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on September 22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Viking Therapeutics’ promising position in the market. The company’s competitive efficacy and safety data from its oral and subcutaneous GLP-1 programs stand out as significant strengths. These programs not only demonstrate Viking’s robust pipeline but also position the company as an attractive candidate for potential mergers and acquisitions.
Despite the competitive landscape, with major players like Eli Lilly and Novo Nordisk, Pantginis remains optimistic about Viking’s prospects. The ongoing debates around competition and execution do not overshadow the potential growth and strategic opportunities that Viking presents. This positive outlook is further reinforced by the company’s ability to navigate investor psychology effectively, maintaining a strong position in the industry.
Pantginis covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Travere Therapeutics, and Krystal Biotech. According to TipRanks, Pantginis has an average return of -5.7% and a 39.41% success rate on recommended stocks.
In another report released on September 22, BTIG also reiterated a Buy rating on the stock with a $125.00 price target.